Total hospitalizations after peripheral arterial revascularization in the VOYAGER trial
نویسندگان
چکیده
Abstract Background In the VOYAGER PAD trial, rivaroxaban reduced first and total (first subsequent) occurrences of major adverse limb cardiovascular events in patients with peripheral artery disease (PAD) after lower extremity revascularization (LER), but also increased incident bleeding. Purpose Assessment burden by onset a particular set does not necessarily capture all consequences process that negatively impact patients' quality life, motivating adoption more patient-centered outcomes. The present analysis describes incidence duration hospitalizations reported during study as broader measure net benefit therapy. Methods Patients were randomized 1:1 to 2.5 mg twice daily plus aspirin (n=3286) or alone (n=3278). Investigators documented primary reason for each hospitalization occurring randomization. Total rates estimated per 100 patient-years. Treatment group comparisons on time-to-event outcome marginal proportional hazards models death competing terminal event, while days hospital compared zero-inflated Poisson regression. All analyses intention-to-treat. Results A 7156 (3265 first, 3891 occurred median years follow-up, nearly 40% being small fraction attributed bleeding (Figure 1). rate was higher event hospitalizations, prevented than caused (Table Mean among hospitalized at least once significantly any reason, PAD, bleeding, so numerically rivaroxaban. Conclusion undergoing LER have high subsequent an index procedure, driven re-hospitalizations PAD. Rivaroxaban decreased both hospitalizations. While due mean durations these relative placebo, leading fewer (1252 vs. 1531 days). These findings may be useful clinicians weighing risks benefits revascularization. Funding Acknowledgement Type funding sources: Private company. Main source(s): BayerJanssen
منابع مشابه
Surgical infrainguinal revascularization for peripheral arterial disease: factors affecting patency rate
Background: Peripheral arterial disease is a source of morbidity and mortality. Surgical vascular reconstruction is a treatment option but probability of failure and complications are important concerns. In this study, we evaluated outcome of surgical infrainguinal reconstruction and factors affecting graft patency for a period of one year. Methods: In this cohort study, 85 consecutive patie...
متن کاملTotal arterial revascularization: A superior method of cardiac revascularization.
For over 40 years, the left internal thoracic artery has been used as the gold standard for myocardial revascularization and anastomosis over the left anterior descending artery due to its excellent patency rates. However, the right internal thoracic artery behaves in the same manner as the left, also having excellent long-term patency. Hence, no patient should be deprived of the benefits of to...
متن کاملPercutaneous revascularization for peripheral arterial disease: paclitaxel saves the day.
Patients presenting with femoropopliteal (FP) disease often require revascularization for lifestyle-limiting claudication medical therapy that failed, or for critical limb ischemia. Percutaneous revascularization for FP disease has been fraught with challenges since the initial description of percutaneous transluminal balloon angioplasty (PTA) of the FP artery. Due to high rates of arterial dis...
متن کاملTotal Arterial Revascularization in Coronary Artery Bypass Grafting Surgery
Coronary artery bypass graft (CABG) operations are one of the most commonly performed sur‐ gical procedures, with a worldwide prevalence of over 800,000 annually and more than 350,000 operations being performed in the United States each year [1]. The use of the left internal mam‐ mary artery (LIMA) is widely considered to be the gold standard for conventional CABG opera‐ tions. Its use has been...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Heart Journal
سال: 2022
ISSN: ['2634-3916']
DOI: https://doi.org/10.1093/eurheartj/ehac544.1982